What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower.
周三，Madrigal Pharmaceuticals股票 (纳斯达克: MDGL) 和Sagimet Biosciences股票 (纳斯达克: SGMT) 价格走低。
At the EASL International Liver Congress 2024, Eli Lilly And Co (NYSE:LLY) shared an abstract highlighting fibrosis results from a Phase 2 trial of tirzepatide in patients with metabolic dysfunction-associated steatohepatitis (MASH).
在2024年EASL国际肝病大会上，Eli Lilly And Co股票 (纽交所: LLY) 分享了一项关于tirzepatide一期试验中代谢紊乱相关脂肪肝炎(MASH)患者的纤维化结果的摘要。
Tirzepatide is a key ingredient in popular Mounjaro for diabetes and Zepbound for weight loss.
tirzepatide是主流币Mounjaro和Zepbound的关键成分之一，用于治疗糖尿病和减肥。
Other companies working on MASH candidates include 89bio Inc (NASDAQ:ETNB), Akero Therapeutics Inc (NASDAQ:AKRO), and Viking Therapeutics Inc (NASDAQ:VKTX).
其他正在研究治疗MASH产品的公司包括89bio股票(纳斯达克: ETNB)，Akero Therapeutics股票(纳斯达克: AKRO)和Viking Therapeutics股票(纳斯达克: VKTX)。
The Phase 2 SYNERGY-NASH trial studied three doses (5 mg, 10 mg or 15 mg) of tirzepatide in 190 people. End-of-treatment liver biopsies were available for 157 participants.
SYNERGY-NASH一期试验研究了tirzepatide的3种剂量（5毫克、10毫克或15毫克）对190名患者的疗效。157 名参与者末期治疗时都有肝活检报告。
The proportion of participants who achieved MASH resolution without worsening of fibrosis was 9.8% for placebo, 43.6% for 5 mg, 55.5% for 10 mg and 62.4% for 15 mg.
安慰剂组中达到MASH缓解但不加重纤维化的参与者比例为9.8％, 5毫克组为43.6％, 10毫克组为55.5％，15毫克组为62.4％。
Among 155 participants who completed the study on treatment with evaluable biopsies, the primary endpoint of MASH resolution without worsening of fibrosis was achieved by 51.8%, 62.8%, and 73.3% for tirzepatide 5 mg, 10 mg, and 15 mg, respectively, compared with 13.2% for placebo.
在接受评估肝活检的155名患者中，5毫克、10毫克和15毫克tirzepatide组的MASH缓解率分别达到51.8％、62.8％和73.3％，安慰剂组为13.2％。
The proportion who achieved ≥ 1-stage fibrosis improvement without worsening of MASH was 29.7% for placebo, 54.9% for tirzepatide 5 mg, 51.3% for tirzepatide 10 mg, and 51.0% for tirzepatide 15 mg.
安慰剂组中实现≥ 1级纤维化改善但不加重MASH的比例为29.7％，5毫克组为54.9％，10毫克组为51.3％，15毫克组为51.0％。
A reduction in nonalcoholic fatty liver disease activity score (NAS) by ≥ 2 points was achieved by 71.7% to 78.3% of participants across the three tirzepatide dose groups and by 36.7% with placebo. Body weight was reduced by up to 17.3% with tirzepatide.
三个tirzepatide剂量组中71.7％至78.3％的参与者降低了非酒精性脂肪肝疾病活动得分(NAS)，安慰剂组为36.7％。tirzepatide可减轻体重长达17.3％。
Liver enzymes and fat decreased, and serum and imaging biomarkers of liver inflammation and fibrosis significantly improved in the tirzepatide groups compared to the placebo.
与安慰剂组相比，tirzepatide组的肝酶和脂肪降低，并且肝脏炎症和纤维化的血清和影像生物标志物明显改善。
The abstract added that there was a lack of a clear dose relationship in achieving MASH resolution without worsening the fibrosis endpoint.
摘要补充说，在实现MASH缓解且不恶化纤维化终点的剂量关系方面，没有明确的剂量关系。
Larger and longer trials are needed to assess the efficacy and safety of tirzepatide for non-cirrhotic MASH.
需要更大规模和更长时间的试验来评估非肝硬化型MASH的tirzepatide疗效和安全性。
Related: FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring.
相关:美国FDA有条件批准Madrigal Pharmaceuticals的Resmetirom作为脂肪肝病的首个治疗药物。
Price Action: MDGL shares are down 5.14% at $231.78, and SGMT shares are down 7.22% at $4.66 at the last check on Wednesday.
截至周三最后一次交易，MDGL股票以231.78美元下跌5.14％，SGMT股票以4.66美元下跌7.22％。